摘要
目的探讨BP1同源盒基因在乳腺癌中的表达及其与临床病理指标的关系。方法收集165例乳腺癌临床和病理资料,采用原位杂交法检测BP1的表达,同时用二步法进行ER、p53、PCNA、bcl2、cerbB2免疫组化染色。结果BP1基因表达率为67.88%,免疫组化:ER70.30%、p5349.09%、PCNA74.55%、bcl253.33%、cerbB275.52%。BP1与bcl2具有相关性(P<0.01),且均与ER相关(P<0.05),与p53呈负相关(P<0.05)。BP1与PCNA、cerbB2、患者年龄、组织学类型、淋巴结转移等无相关性。结论BP1可能通过某种非依赖p53基因调控机制,与bcl2、ER协同抑制肿瘤细胞的凋亡而参与乳腺癌的发生。
Purpose To explore the expression of BP1 gene in breast cancer and its relationship with clinicopathological factors. Methods Clinical and pathological data of 165 patents of breast cancer were analyzed.The expression of BP1 gene mRNA was detected by in situ hybridization.Immunohistochemistry staining for ER,p53,PCNA,bcl-2 and c-erbB-2 was carried out with the two step method. Results The overall positive rates of BP1 gene in breast cancer was 67.88%. The positive rates of ER,p53,PCNA,bcl-2 and c-erbB-2 were 70.30%、49.09%、74.55%、53.33% and 75.52%,respectively. A significant relationship was observed between the expression of BP1 and the statue of bcl-2 (P<0.01). Both of them displayed a close correlation with ER and p53 (P<0.05). Conversely,the expression of BP1 did not correlate with the status of PCNA,c-erbB-2,age,histological type and lymph node metastasis. Conclusions Cooperating with bcl-2 and ER,BP1 may play an important role in inhibiting breast cancer cell apoptosis through p53 gene independence pathway.
出处
《临床与实验病理学杂志》
CAS
CSCD
北大核心
2005年第3期269-272,共4页
Chinese Journal of Clinical and Experimental Pathology
